Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study

ABSTRACT

Background

The purpose of this study was to observe the safety and efficacy of CalliSpheres microspheres drug-eluting beads (DEB) transhepatic arterial chemoembolization (CSM-TACE) for liver metastasis of gastric cancer (GCLM) combined with trans-arterial infusion therapy (TAIT) as the primary focus of gastric cancer.

Research design and methods

Unresectable advanced GCLM patients were collected for retrospective analysis. Patients who progressed after chemotherapy or could not receive systematic chemotherapy were selected. CSM-TACE was used for GCLM treatment and oxaliplatin for TAIT of primary focus of gastric cancer. Adverse reactions, tumor reactions, survival rate, and survival time during treatment were recorded, and prognostic factors were analyzed.

Results

Forty-three patients from four oncology centers met inclusion criteria and were enrolled. CSM-TACE averaged (1.51 ± 0.51) times and TAIT averaged (4.58 ± 1.65) times. The follow-up time was 2.5–49 months, and the 6-month, 1-year, and 2-year survival rates were 86.0%, 72.1%, and 41.9%, respectively, with a median overall survival of 11.5 months. The adverse reactions during treatment were grade 1–3. The hazard ratio (HR) of combination therapy was 0.51 (P = 0.040), and the HR of TAIT frequency was 0.34 (P = 0.002), which were independent protective factors affecting prognosis.

Conclusions

CSM-TAC for GCLM combined with TAIT for primary focus of gastric cancer is safe and efficacious, which is worthy of clinical promotion and application.

KEYWORDS:

• CalliSpheres microspheres
• CSM-TACE
• Gastric cancer
• Liver metastases
• Efficacy and safety

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Ethical approval

The study was approved by the Ethics Committee of Affiliated Zhongshan Hospital of Dalian University, the Second Hospital of Dalian Medical University, the First Hospital of China Medical University, and Linyi Cancer Hospital. All patients participating in the study have signed the informed consent. All methods were performed in accordance with the relevant guidelines and regulations.

Data availability statement

All data generated or analyzed during this study are included in this published article.

Author contribution statement

JBS and YXS: responsible for clinical trial research and paper writing; SL, FX, and JM: responsible for patient follow-up and data statistics; CL, JZ, and RYW: responsible for experiment management; FG, SNL, and GSZ: responsible for project design and experimental implementation. All authors read and approved the final manuscript.

Additional information

Funding

This paper received no funding.